Clinical significance of the CCR5delta32 allele in hepatitis C

Publication

Clinical significance of the CCR5delta32 allele in hepatitis C

Journal Paper/Review - Sep 5, 2014

Morard Isabelle, Negro Franco, Bochud Pierre-Yves, Pascarella Stéphanie, Semela David, Mullhaupt Beat, Moradpour Darius, Malinverni Raffaele, Heim Markus, Gorgievski Meri, De Gottardi Andrea, Cerny Andrea, Mangia Alessandra, Calmy Alexandra, Clément Sophie, Swiss Hepatitis C Cohort Study Group

Citation

Morard I, Negro F, Bochud P, Pascarella S, Semela D, Mullhaupt B, Moradpour D, Malinverni R, Heim M, Gorgievski M, De Gottardi A, Cerny A, Mangia A, Calmy A, Clément S, Swiss Hepatitis C Cohort Study Group. Clinical significance of the CCR5delta32 allele in hepatitis C. PloS one 2014; 9:e106424.

Type

Journal Paper/Review (English)

Journal

PloS one 2014; 9

Publication Date

Sep 5, 2014

Issn Electronic

1932-6203

Pages

e106424

Brief description/objective

BACKGROUND
The CCR5 receptor, expressed on Th1 cells, may influence clinical outcomes of HCV infection. We explored a possible link between a CCR5 32-base deletion (CCR5delta32), resulting in the expression of a non-functioning receptor, and clinical outcomes of HCV infection.

METHODS
CCR5 and HCV-related phenotypes were analysed in 1,290 chronically infected patients and 160 patients with spontaneous clearance.

RESULTS
Carriage of the CCR5delta32 allele was observed in 11% of spontaneous clearers compared to 17% of chronically infected patients (OR = 0.59, 95% CI interval 0.35-0.99, P = 0.047). Carriage of this allele also tended to be observed more frequently among patients with liver inflammation (19%) compared to those without inflammation (15%, OR = 1.38, 95% CI interval 0.99-1.95, P = 0.06). The CCR5delta32 was not associated with sustained virological response (P = 0.6), fibrosis stage (P = 0.8), or fibrosis progression rate (P = 0.4).

CONCLUSIONS
The CCR5delta32 allele appears to be associated with a decreased rate of spontaneous HCV eradication, but not with hepatitis progression or response to antiviral therapy.